{"organizations": [], "uuid": "a500602b470466646135d435057bcd0b29d4b6a7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cvs-health-reports-q1-gaap-eps-098/brief-cvs-health-reports-q1-gaap-eps-0-98-from-continuing-operations-idUSASC09YX4", "country": "US", "domain_rank": 408, "title": "BRIEF-CVS Health Reports Q1 GAAP EPS $0.98 From Continuing Operations", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:21:00.000+03:00", "replies_count": 0, "uuid": "a500602b470466646135d435057bcd0b29d4b6a7"}, "author": "", "url": "https://www.reuters.com/article/brief-cvs-health-reports-q1-gaap-eps-098/brief-cvs-health-reports-q1-gaap-eps-0-98-from-continuing-operations-idUSASC09YX4", "ord_in_thread": 0, "title": "BRIEF-CVS Health Reports Q1 GAAP EPS $0.98 From Continuing Operations", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-cvs health reports", "sentiment": "negative"}, {"name": "cvs health corp", "sentiment": "none"}, {"name": "cvs", "sentiment": "none"}, {"name": "operations reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "cvs health corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:23 AM / Updated 21 minutes ago BRIEF-CVS Health Reports Q1 GAAP EPS $0.98 From Continuing Operations Reuters Staff\nMay 2 (Reuters) - Cvs Health Corp:\n* CVS HEALTH REPORTS FIRST QUARTER RESULTS AND CONFIRMS 2018 FULL YEAR OUTLOOK * CVS HEALTH CORP Q1 SAME STORE SALES ROSE 5.8 PCT\n* CVS HEALTH CORP Q1 GAAP SHR $0.98 FROM CONTINUING OPERATIONS\n* CVS HEALTH CORP Q1 SHR VIEW $1.41 — THOMSON REUTERS I/B/E/S * CVS HEALTH CORP SEES FY 2018 ADJUSTED SHR $6.87 TO $7.08\n* CVS HEALTH CORP SEES FY 2018 GAAP SHR $5.11 TO $5.32 FROM CONTINUING OPERATIONS\n* CVS HEALTH CORP - EXPECTS FULL YEAR GAAP OPERATING PROFIT GROWTH OF DOWN 0.25% TO UP 2.75%\n* CVS HEALTH CORP - CONFIRMED ITS PREVIOUS ADJUSTED CONSOLIDATED OPERATING PROFIT GROWTH GUIDANCE FOR FULL YEAR OF DOWN 1.5% TO UP 1.5%\n* CVS HEALTH CORP FY2018 SHR VIEW $6.30 — THOMSON REUTERS I/B/E/S\n* CVS HEALTH CORP QTRLY SAME STORE SALES INCREASED 5.8% AND PHARMACY SAME STORE SALES INCREASED 7.3%\n* CVS HEALTH CORP - EXPECTS Q2 GAAP OPERATING PROFIT GROWTH OF 5.25% TO 8.5%\n* CVS HEALTH CORP - EXPECTS Q2 ADJUSTED CONSOLIDATED OPERATING PROFIT GROWTH OF FLAT TO UP 3.25%\n* CVS HEALTH CORP - EXPECTS TO DELIVER GAAP DILUTED EPS OF $1.21 TO $1.26 AND ADJUSTED EPS OF $1.59 TO $1.64 IN Q2\n* CVS HEALTH CORP Q2 SHR VIEW $1.41 — THOMSON REUTERS I/B/E/S\n* CVS HEALTH CORP - FRONT STORE SAME STORE SALES INCREASED 1.6% IN THREE MONTHS ENDED MARCH 31, 2018, COMPARED TO PRIOR YEAR\n* CVS HEALTH - MOVING FORWARD ON BOTH REGULATORY, INTEGRATION PLANNING FRONTS IN SUPPORT OF A CLOSE IN SECOND HALF OF THIS YEAR FOR AETNA TRANSACTION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:21:00.000+03:00", "crawled": "2018-05-02T15:33:07.048+03:00", "highlightTitle": ""}